MX2023001881A - Tratamiento con ribitol. - Google Patents

Tratamiento con ribitol.

Info

Publication number
MX2023001881A
MX2023001881A MX2023001881A MX2023001881A MX2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A
Authority
MX
Mexico
Prior art keywords
ribitol
treatment
disorder
disease
treating
Prior art date
Application number
MX2023001881A
Other languages
English (en)
Inventor
Qi Long Lu
Bo Wu
Original Assignee
The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health filed Critical The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health
Publication of MX2023001881A publication Critical patent/MX2023001881A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Molecular Biology (AREA)

Abstract

Se proporcionan métodos para tratar una enfermedad o trastorno en un sujeto que lo necesita y composiciones asociadas. Se administra una cantidad eficaz de ribitol, lo que restaura y/o potencia la glucosilación funcional de ()(-DS y/o trata la enfermedad o trastorno.
MX2023001881A 2020-09-10 2021-09-09 Tratamiento con ribitol. MX2023001881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (1)

Publication Number Publication Date
MX2023001881A true MX2023001881A (es) 2023-04-03

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001881A MX2023001881A (es) 2020-09-10 2021-09-09 Tratamiento con ribitol.

Country Status (10)

Country Link
US (1) US20230364118A1 (es)
EP (1) EP4210708A1 (es)
JP (1) JP2023544249A (es)
KR (1) KR20230069941A (es)
CN (1) CN117355310A (es)
AU (1) AU2021338706A1 (es)
CA (1) CA3191582A1 (es)
IL (1) IL301088A (es)
MX (1) MX2023001881A (es)
WO (1) WO2022056137A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020041750A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Also Published As

Publication number Publication date
KR20230069941A (ko) 2023-05-19
JP2023544249A (ja) 2023-10-23
AU2021338706A1 (en) 2023-05-25
WO2022056137A1 (en) 2022-03-17
EP4210708A1 (en) 2023-07-19
US20230364118A1 (en) 2023-11-16
IL301088A (en) 2023-05-01
WO2022056137A9 (en) 2022-04-14
CA3191582A1 (en) 2022-03-17
CN117355310A (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
BR112022007677A2 (pt) L-asparaginase recombinante
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
WO2004004757A8 (en) Treatment for eye disorder
EP1556068A4 (en) TREATMENT OF AUTISM AND SIMULTANEOUS DISEASES
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
MX2023001881A (es) Tratamiento con ribitol.
MX2023006146A (es) Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped.
MX2022014356A (es) Ciertas composiciones quimicas y metodos de uso de las mismas.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
WO2023009834A3 (en) Methods of treating cancer
MX2022010945A (es) Usos terapeuticos de compuestos macrociclicos.
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
WO2021226442A3 (en) Therapeutic uses of c3-binding agents
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.